Abstract B122: The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design
It is shown that GEM followed by RAS inhibitor (GEM→RASi) scheduling is associated with improved survival and altered tumor growth dynamics relative to reverse scheduling and monotherapies, and favorable survival trends compared to concurrent treatment, with reduced total agent exposure.